http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BG-1161-U1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f058a71899e153cedc18883bad5b31a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 |
| filingDate | 2008-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a947852fb2a3a425f05d96f316b32b80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31998515e90bc4fec5c71e9a9ee46a4e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4246b7673f7ddc1e5f90aef1facd2db4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58e9f26d34947b91155306b8753aa4c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_249c4870190e3c0ec600da6e1b64a50e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7b14db6be6e55b804998e444d26514d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0594ce1abf59b4e575a156257fd2c760 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fc9f3f15d06a98711e98bf1e99493c0 |
| publicationDate | 2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BG-1161-U1 |
| titleOfInvention | PHARMACEUTICAL COMPOSITION CONTAINING TROXCERUTINE |
| abstract | The useful model relates to a pharmaceutical composition comprising the active substance troxerutin, which has a vetonic (anti-arachial), capillary, anti-exudative and haemostatic action. It suppresses platelet aggregation. The new composition, according to the useful model, contains 300 mg of troxerutin and excipients, the ratio of troxerutin to excipients being from 1: 0.01 to 1: 0.20. In one embodiment of the utility model, the pharmaceutical composition comprises 300 mg of troxerutin and the excipients: lactose from 0.1 to 10.0% % and magnesium stearate from 0.1 to 5.0 wt. % or sodium stearyl fumarate from 0.1 to 3.0 wt. % or talc of from 0.1 to 10 wt. % based on the total mixture. In another embodiment of the utility model, the pharmaceutical composition comprises 300 mg of troxerutin and adjuvants: lactose from 0.1 to 3.0 wt. %, magnesium stearate from 0.1 to 5.0 wt. % or sodium stearyl fumarate from 0.1 to 3.0 wt. % or talc of from 0.1 to 10 wt. %, colloidal silicon dioxide from 0.1 to 4.0 wt. % and polyethylene glycol of from 0.1 to 6.0 moles. %. |
| priorityDate | 2008-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.